A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer

Figure 2

Restaging CT post 9 cycles of Nivolumab. There was a reduction of the RLL mass post 9 cycles of Nivolumab.